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Abstract 
Purpose:  
CDK4/6 inhibitors are used to treat ER+ metastatic breast cancer (BC) in 
combination with endocrine therapy. PALLET is a phase II randomized trial 
evaluating the effects of palbociclib with letrozole combination as neo-adjuvant 
therapy. 
Patients and methods:  
Postmenopausal women with ER+ primary BC and tumors ≥2.0cm were randomized 
3:2:2:2: A: letrozole (2.5mg/d), 14 weeks; B: letrozole, two weeks then 
palbociclib+letrozole to 14 weeks; C: palbociclib, two weeks then 
palbociclib+letrozole to 14 weeks; D: palbociclib+letrozole, 14 weeks. Palbociclib 
was given 125mg/d PO on a 21-days-on, 7-days-off schedule. Core-cut biopsies 
were taken at baseline, two, and 14 weeks. Co-primary endpoints for letrozole vs 
palbociclib+letrozole groups (A vs B+C+D) were: change in Ki67 (IHC) between 
baseline and 14 weeks and clinical response (ordinal, ultrasound) after 14 weeks. 
Complete cell-cycle arrest (CCCA) was defined as Ki67≤2.7%. Apoptosis was 
characterized by c-PARP. 
Results:  
307 patients were recruited. Clinical response was not significantly different between 
palbociclib+letrozole vs letrozole groups (p=0.20; CR+PR 54.3% vs 49.5%).  PD was 
3.2% vs 5.4% respectively. Median log-fold change in Ki67 was greater with 
palbociclib+letrozole vs letrozole (−4.1 vs −2.2; p<0.001) in the 190 (61.9%) 
evaluable patients corresponding to a geometric mean change of −97.4% vs 
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−88.5%. More patients on palbociclib+letrozole achieved CCCA (90% vs 59%, 
p<0.001). Median log-fold change (suppression) of c-PARP was greater with 
palbociclib+letrozole vs letrozole (−0.80 vs −0.42; p<0.001). More patients had grade 
≥3 toxicity on palbociclib+letrozole (49.8% vs 17.0%; p<0.001) mainly due to 
asymptomatic neutropenia. 
Conclusion:  
Adding palbociclib to letrozole significantly enhanced the suppression of malignant 
cell proliferation (Ki67) in primary ER+ BC, but did not increase the clinical response 
rate over 14-weeks possibly related to concurrent reduction in apoptosis. 
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Introduction 
The use of endocrine therapy for the treatment of hormone receptor positive (HR+) 
breast cancer (BC) is a seminal example of successfully targeted cancer treatment. 
Nonetheless, endocrine therapy resistance either de novo or acquired remains a 
challenge in patients with both early and advanced BC1-4. One approach to reverse 
resistance to standard endocrine therapy has been to target an alternative pathway. 
The cyclin-dependent kinases, CDK4 and CDK6, promote progression from G1 
phase to the S phase of the cell cycle. Inhibition of these kinases leads to decreased 
proliferation of estrogen-receptor positive (ER+) tumors and reverses endocrine 
resistance in some patients. The CDK4/6 inhibitor, palbociclib (Ibrance, Pfizer), has 
demonstrated considerable activity when combined with other endocrine therapies in 
patients with metastatic BC in both first-line and second-line settings5-8, with recent 
results showing prolonged overall survival in the second-line setting9. Large phase III 
adjuvant BC trials with palbociclib and other CDK4/6 inhibitors are ongoing (PALLAS 
- NCT02513394, PENELOPE-B - NCT01864746, MONARCH-E - NCT03155997). 
In early BC the use of neo-adjuvant therapy is an attractive option to facilitate breast 
conservation and, critically, enables assessment of in vivo biomarkers to identify 
proof of principle activity or to predict responsive or resistant subgroups of 
tumors10,11.  The achievement of a pathological complete response (pCR) in HR+ 
cancers to chemotherapy is much less common than in other subtypes of BC. . A 
recent meta-analysis reported similar clinical responses and achievement of breast 
conservation in HR+ BC with neo-adjuvant endocrine therapy compared with 
combination chemotherapy, but with lower toxicity12.  As such, strategies to further 
improve response to neo-adjuvant endocrine therapy in HR+ cancers are more 
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relevant than using chemotherapy. In HR+ disease, decrease in the proliferation 
marker Ki67 from baseline in response to endocrine therapy has been validated as a 
marker of treatment benefit, with measurement of Ki67 after two weeks of endocrine 
therapy shown to improve the prediction of recurrence-free survival (RFS)13,14. Given 
the predominantly anti-proliferative effects of palbociclib, suppression of Ki67 is a 
rational endpoint for estimating whether there is efficacy in adding palbociclib to an 
aromatase inhibitor (AI) vs AI alone in the neo-adjuvant setting.  
Here, we report the results of PALLET, a large, multi-national, neo-adjuvant 
randomized trial (NCT02296801, ISRCTN31243262), designed with co-primary 
endpoints examining the biological and clinical effects of neo-adjuvant letrozole with 
or without palbociclib for 14 weeks as primary treatment of ER+/HER2- early 
invasive BC.  
Methods 
Full details of the methodology are available in the supplementary material. In 
summary: 
Trial Design and Patients 
PALLET is a phase II randomized multicenter trial with parallel UK and North 
American protocols. Patients were recruited from 38 sites in the UK, USA, and 
Canada. Eligible patients were postmenopausal women with unilateral, operable, 
ER+, HER2- tumors measuring at least 2cm by ultrasound, with no evidence of 
metastatic disease. ER positivity and HER2 negativity were defined as per the 
ASCO/CAP guidelines15,16 and were locally assessed.  
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Patients were randomized (3:2:2:2 ratio) to one of four treatment groups. Group A 
received letrozole alone for 14 weeks; Group B received letrozole for two weeks 
followed by palbociclib+letrozole to 14 weeks; Group C received palbociclib for two 
weeks followed by palbociclib+letrozole to 14 weeks; Group D received 
palbociclib+letrozole for 14 weeks (Figures S1 and S2). The parallel 4-group design 
with a two week change for groups B+C enabled the role of each drug alone, or in 
combination, in suppressing Ki67 to be assessed. Ki67 was centrally assessed. 
Treatment allocation was by computer generated random permuted blocks and 
stratified by geographic location: United Kingdom vs North America (USA and 
Canada) (see supplementary material for further details of randomization methods).  
Letrozole was given as 2.5mg/d PO continually and palbociclib was given as 
125mg/d PO on a 21-days-on, 7-days-off schedule. Protocol specified dose 
modifications for palbociclib were recommended for various adverse events.  
Procedures 
Following randomization, patients visited clinic weekly for the first four weeks, then 
every other week until week 14. Follow-up visits were 30 days post trial treatment 
and 12 months after randomization. Assessments required at these visits are 
described in the protocol.  
Core-cut biopsies and trial specific blood samples were taken at baseline (post-
randomization), two weeks (prior to commencement of second drug for groups B+C), 
and 14 weeks or discontinuation of study therapy (within 48 hours of last dose of trial 
treatment).  
Outcomes 
 PALLET manuscript v3.0  9 
 
Principal outcome analyses focused on changes between baseline and end of 
treatment (EoT) and compared letrozole (A) with palbociclib+letrozole (B+C+D). The 
co-primary endpoints were (i) clinical response (ultrasound- ECOG17) and (ii) change 
in the proliferation marker Ki67 (IHC). Secondary endpoints included pCR, changes 
in surgical intent, and safety. Additionally, changes in Ki67 between baseline and 
week two and week two to EoT were compared for groups in which treatment 
differed during each respective time period. Pre-specified exploratory biomarkers 
included c-PARP (apoptosis).  
Statistical Analysis 
The PALLET trial was powered (90%) using a conventional comparative design with 
alpha (α=5% overall) split between the two co-primary endpoints. Improved clinical 
response would be detected for palbociclib+letrozole over letrozole [CR: 31% vs 
21%; PR: 57% vs 54%; SD 5% vs 15%; PR: 2% vs 5%] with 284 patients, α=4% and 
90% power. With a 5% non-evaluable rate and 3:2:2:2 allocation ratio, the 
recruitment target was 306 patients. Improvement with decreased Ki67 from 80% in 
group A to 90% in groups B+C+D (log-fold change of -0.693; SD=1.5) would be 
detected with 279 patients with α=1% and 90% power. Interim analyses were 
planned at 25% and 50% of trial endpoint information and the trial would have 
terminated for futility at the second analysis if there was no evidence that either 
endpoint favored palbociclib. 
Post-hoc analysis revealed that there were 279 evaluable clinical responses 
(93:186), which under the initial sample size specifications would give 88.1% power. 
Log-fold changes in Ki67 were available for 190 (61.9%) patients (65:125), to provide 
75% power. 
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All patients were analyzed following the intention to treat approach. Clinical response 
was treated as an ordinal outcome and compared using the Mann-Whitney test in all 
patients with ECOG response data available at EoT. Changes in Ki67 and c-PARP 
were analyzed on the natural log fold scale in patients with biopsy data available at 
both baseline and EoT. As an exploratory analysis, complete cell cycle arrest 
(CCCA) at EoT (defined as a Ki67≤2.7%) was compared between groups using a 
logistic regression model adjusting for recruitment region and histological type.  
Results 
Between February 27, 2015 and March 8, 2018, 307 women were recruited; 166 
from the UK (Table S1) and 141 from North America (Table S2) (Group A 103, 
Group B 68, Group C 69, Group D 67; Figure 1). Baseline demographic and clinical 
characteristics were similar across treatment groups (Table 1).  
Overall, 253 (82.4%) patients completed 14 weeks treatment. In the letrozole group 
(A) this was 85% (n=88) compared with 81% (n=165) of patients receiving 
palbociclib+letrozole (B+C+D). The median percentage of scheduled letrozole 
received was 99% in all treatment groups. The median (IQR) percentage of the 
scheduled dose of palbociclib received in groups B, C, and D were 99.2% (82.9-
100.0), 90.9% (67.8-100.0), and 97.4% (79.2-100.0), respectively. Palbociclib was 
interrupted/delayed in 21.6% (n=44) of patients, dose was reduced in 2.0% (n=4) of 
patients and treatment was interrupted/delayed and dose reduced in 15.2% (n=31) 
(Table S3). 
Clinical response outcomes at EoT were available for 279 (90.8%) patients (Table 
2). In the letrozole group (A), 46/93 (49.5%) achieved a complete or partial response 
compared to 101/186 (54.4%) with palbociclib+letrozole (B+C+D). There was no 
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evidence that the inclusion of palbociclib changed clinical response as measured by 
ultrasound (p=0.20). 
The log-fold changes in Ki67 were available for 190 (61.9%) patients (Figure 2, 
Table 2). Reasons for non-availability of paired Ki67 results included missing and 
unevaluable samples (Table S4) with histological type and geographical region the 
only baseline characteristics differentiating availability. The median log-fold change 
in Ki67 between baseline and EoT was −2.2 (IQR: −3.4 to −1.0) in the letrozole 
group (A) compared with −4.1 (IQR: −5.0 to −2.8; one-sided p<0.001) in 
palbociclib+letrozole groups (B+C+D). This corresponds to a geometric mean 
change of −88.5% (95% CI: −92.3 to −82.9%), compared to −97.4% (95% CI: −98.1 
to −96.4%). The geometric mean ratio was 0.16 (95% CI: 0.13 to 0.18; p<0.001). 
CCCA was observed in 38/65 (58.5%) patients in the letrozole group (A) compared 
to 113/125 (90.4%) in palbociclib+letrozole groups (B+C+D) (OR=6.83; 95% CI: 3.12 
to 14.98; p<0.001). 
Between baseline and week two there was a median (IQR) log-fold change in Ki67 
with letrozole alone (A+B) of −1.3 (−2.9 to −0.7) compared with −3.1 (−4.1 to −1.5) in 
palbociclib alone (C) (p<0.001). The median (IQR) log-fold change in Ki67 at week 
two with palbociclib+letrozole (D) was −3.9 (−4.7 to −2.7; p<0.001) compared with 
groups who received letrozole alone for the first two weeks (A+B), and there was no 
significant difference between palbociclib alone (C) and palbociclib+letrozole (D) 
(p=0.06). At week two, CCCA was more common with palbociclib+letrozole than with 
palbociclib alone (D: 47/53 (89%; 95% CI: 76% to 96%) vs C: 44/61 (72%; 95% CI: 
59% to 82%) (p=0.04). Between week two and week 14, there was a median (IQR) 
log-fold change in Ki67 of −0.1 (−1.1 to 0.4) with letrozole alone (A) compared with 
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−2.1 (−3.5 to −1.3; p<0.001), −0.4 (−2.1 to 0.0; p=0.12), and 0.0 (−0.1 to 0.9; p=0.08) 
with palbociclib+letrozole (B, C, D), respectively. 
Pathological complete response (pCR) in the breast occurred infrequently and there 
was no evidence of a difference between letrozole (A) (1/87; 1.1%; 95% CI: 0.0 to 
6.2) compared with palbociclib+letrozole (B+C+D) (6/180; 3.3%; 95% CI: 1.2 to 7.1; 
p=0.43).  pCR in breast, axillary lymph nodes, and non-axillary sentinel nodes were 
found in 2/180 (1.1%; 95% CI: 0.0 to 4.0; p=1.00) patients receiving 
palbociclib+letrozole (B+C+D). There was no difference in the proportion of patients 
whose intended surgery changed from mastectomy at baseline to breast 
conservation at week 14 with letrozole (A) (13/92; 14.1%; 95% CI: 7.7 to 23.0%) 
compared with palbociclib+letrozole (B+C+D) (25/177; 14.1%; 95% CI: 9.4 to 20.1; 
p=1.00). 
Apoptosis, as measured by c-PARP, was a pre-specified exploratory biomarker with 
paired data available for 146 (47.6%) patients (Figure 3, Table 2). Other pre-
specified exploratory biomarkers are under analysis but not yet available to report. 
The log-fold change in c-PARP between baseline and EoT was −0.42 (IQR: −0.99 to 
0.20) with letrozole (A) compared with −0.80 (IQR: −1.35 to −0.29; one-sided 
p<0.001) with palbociclib+letrozole (B+C+D). Post-hoc analyses found that at week 
two there was a median (IQR) log-fold change in c-PARP with letrozole (A+B) of 
−0.1 (−0.6 to 0.2) compared with −0.3 (−0.8 to −0.1) with palbociclib (C) (p=0.004). 
The median (IQR) log-fold change in c-PARP at week two with palbociclib+letrozole 
(D) was −0.5 (−0.7 to 0.0) compared with letrozole (A+B) (p=0.07) and there was no 
evidence of a difference between palbociclib (C) vs palbociclib+letrozole (D) 
(p=0.47). Between week two and week 14, there was a median (IQR) log-fold 
change in c-PARP of −0.3 (−0.7 to 0.0) with letrozole (A) compared with −0.6 (−1.2 
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to −0.3; p=0.09), −0.3 (−1.0 to 0.1; p=0.72), and −0.3 (−0.7 to 0.1; p=0.82) in 
palbociclib+letrozole (B, C, D) groups, respectively. Any grade AE, irrespective of 
relationship to study treatment, was reported in 91% of patients with letrozole (A) 
and 99% of patients with palbociclib+letrozole (B+C+D).  The majority of AEs were 
grade 1 or 2 (91%). Grade ≥3 AEs were reported in 17% of patients with letrozole (A) 
and 50% in palbociclib+letrozole groups (B+C+D) (p<0.001) (Table 3). In total, eight 
patients in palbociclib+letrozole groups (B+C+D) experienced ten events with 
CTCAE grade of 4 or 5. Of these, one patient experienced a grade 5 acute 
respiratory distress syndrome which was considered to be unrelated to letrozole or 
palbociclib. 
Discussion 
PALLET is the largest randomized trial of a CDK4/6 inhibitor in the neo-adjuvant 
setting, and demonstrates that the addition of palbociclib to letrozole markedly 
enhanced the suppression of malignant cell proliferation as assessed by Ki67. In 
addition, there was a significant increase in the number of patients who achieved 
CCCA in their tumor following 14 weeks of combination therapy compared with 
letrozole alone (90% vs 59%). Although the suppression of Ki67 in the first two 
weeks by palbociclib alone was significantly greater than by letrozole alone, the 
combination with palbociclib enhanced the proportion of patients achieving CCCA.  
In terms of toxicity, PALLET detected no new signals by the addition of palbociclib in 
patients with early stage primary BC. 
The lack of difference in clinical response rate (54.3% vs 49.5%) is perhaps not a 
surprise given the cytostatic nature of endocrine based therapies, in contrast to 
similar neo-adjuvant trials using cytotoxic chemotherapies in triple negative BC or 
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targeted combinations in HER2+ BC18. In slower growing ER+ tumors, therapies with 
a predominantly anti-proliferative effect will yield a slower reduction in tumor size19, 
especially over a short time-frame of 14 weeks. When using primary endocrine 
therapy to downstage ER+ BC, maximal tumor shrinkage may take at least 9-12 
months20. We also demonstrate for the first-time (using c-PARP expression as a 
biomarker) that unlike chemotherapy, wherein apoptosis increases in addition to an 
anti-proliferative effect21, CDK4/6 therapy in combination with an AI produces a 
greater suppression (not increase) in apoptosis compared with endocrine therapy 
alone. Measurement of c-PARP is only one of a number of approaches to assessing 
apoptosis in situ. It is notable that the decrease seen in the AI alone arm of PALLET 
is similar to that seen when using the TUNEL method in the IMPACT trial22.  This 
reduction in cell death could also explain why overall tumor volume (i.e. clinical 
response) as determined by ultrasound, did not substantially change, nor did the 
surgical breast conservation rate, despite the markedly enhanced anti-proliferative 
effect. Indeed, these data are consistent with the PALOMA-2 (NCT01740427) study 
in advanced BC, in which the greatest clinical impact was seen in PFS (HR 0.58), 
rather than the best objective response rate (ORR) (55% vs 44%)6,8. Similarly, the 
ORR with abemaciclib+AI in the MONARCH-3 trial was 59% vs 44% with AI alone23 
and with ribociclib+AI in MONALEESA-2 the ORR was 52.7% vs 37.1% with AI 
alone24, yet both studies also had highly significant improvements in PFS (HR 0.54 
and 0.57, respectively). In early BC it remains to be seen whether the anti-
proliferative differences seen in PALLET despite lack of change in ORR in the neo-
adjuvant setting will translate into an impact on time to recurrence in the ongoing 
adjuvant studies. 
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Previous studies of neo-adjuvant endocrine therapy also demonstrated that 
suppression of Ki67, rather than clinical response, is a better indicator of therapeutic 
activity in ER+ early BC. In the IMPACT trial, no difference in clinical response rate 
was seen between anastrozole, tamoxifen, or the combination (37% vs 36% vs 
39%)25 following 3 months of therapy in 330 patients, yet significantly greater 
suppression of Ki67 was reported for anastrozole compared with tamoxifen at 12 
weeks (81.6% vs 61.9%)13,26. These differences in Ki67 suppression were paralleled 
by the greater benefit from anastrozole vs tamoxifen or the combination of 
anastrozole and tamoxifen in the ATAC trial27. Furthermore, the log-fold reduction in 
Ki67 in IMPACT was a predictor of subsequent RFS in the adjuvant setting13. 
Similarly, the greater suppression of Ki67 by letrozole than tamoxifen in P02428 
paralleled the greater improvement in RFS with letrozole in the analogous BIG1-98 
adjuvant trial (NCT00004205)29. When the different AIs were compared in Z1031 
(NCT00265759)14, the lack of difference in Ki67 suppression was supported by 
similar RFS between groups in the adjuvant studies MA-27 (NCT00066573)30 and 
FACE (NCT00248170)31. More recently, the large UK POETIC trial (NCT02338310) 
confirmed that lack of suppression of Ki67 following two weeks of pre-operative AI 
predicted for a significantly worse 5-year relapse-free survival32. CDK4/6 inhibitors 
restrict passage through the cell cycle and are therefore, like endocrine agents, anti-
proliferative. However, whether lack of Ki67 suppression after neoadjuvant CDK4/6 
inhibitor therapy is similarly predictive is as yet unconfirmed.   
The suppression of Ki67 in the first two weeks by palbociclib alone was significantly 
greater than by letrozole alone, a finding also reported recently in the small phase II 
pre-operative palbociclib (POP) trial (NCT02008734)33. However, in PALLET the 4-
group design showed that the palbociclib+letrozole combination enhanced the 
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proportion of patients achieving CCCA in the first two weeks, and that addition of the 
AI maximizes Ki67 suppression. 
In a previous small phase II study (NeoPalAna -  NCT01723774) in 50 patients with 
ER+ early BC of different intrinsic subtypes, sequential biopsies were taken in 
patients initiated on anastrozole for four weeks, followed by the addition of 
palbociclib to study the further change or fall in Ki6734. The rates of CCCA with 
palbociclib and anastrozole were significantly higher (87%) than with anastrozole 
alone (26%), and biomarkers analysis suggested that response to palbociclib 
occurred independently of tumor grade, absence of PgR expression, or mutation in 
p53, PIK3CA, or PTEN genes, but was correlated with RB1 mutation status. 
Extensive gene and protein expression analyses are being undertaken in PALLET as 
exploratory endpoints. These will be correlated with anti-proliferative response, and 
could yield important information about predictive biomarkers for this class of therapy 
in the early BC setting, which can be tested in the adjuvant setting.   
In NeoPalAna, it was reported that palbociclib’s anti-proliferative effect diminished 
rapidly after treatment stopped in some patients, suggesting the need for continued 
therapy34. For this reason in PALLET, we aimed to ensure that the 14-week biopsy 
was taken during exposure to drug therapy, and excluded 2.6% of 14-week samples 
as they fell outside the 48 hour window since last drug dose taken. In addition, 
13.0% of patients had an unevaluable sample which could reflect minimal cellularity 
in the core biopsy. Studies to look at the correlation between the 14-week samples 
with cellularity and Ki67 in the excised surgical sample are ongoing. 
In the only other randomized neo-adjuvant trial of CDK4/6 inhibitors in ER+ early BC 
(NeoMONARCH-NCT02441946), 224 patients were randomized to either 
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anastrozole, abemaciclib (Verzenio, Eli Lilly), or the combination, with biopsies taken 
at baseline, two weeks and after 16 weeks of therapy35. The combination of 
abemaciclib+anastrozole was associated with a greater geometric mean fall in Ki67 
at two weeks (−92.6% vs −63.2%), with a significant increase in CCCA (66% vs 
14%). To date, biomarkers of response or resistance to abemaciclib have not been 
identified, although reports of induced histologic changes suggestive of tumor 
differentiation and increased lymphocytic infiltration were seen in some cases35.  
The incomplete availability of biopsy samples could potentially bias the biological 
findings for Ki67 and c-PARP. When EoT biopsies were not taken (n=38) this often 
occurred with incomplete treatment (n=29; 76%). Excluding these cases could 
overstate the proportion who responded. However, there were an approximately 
equal number of cases in which Ki67 was unevaluable due to scant tumor in the 
biopsy. A similar level of Ki67 suppression would be expected in these cases 
compared to the evaluable population so would not be expected to bias our findings. 
Other trials featuring Ki67 as an endpoint have observed similar evaluable 
proportions. In the NeoMONARCH study, 138/223 (61.9%) patients were evaluable 
for Ki67 compared to 190/307 (61.9%) in our trial.  Analyses of Ki67 and c-PARP 
levels between baseline and week two and from week two to EoT in PALLET were 
conducted post-hoc and did not adjust for multiple testing so should be cautiously 
interpreted. Nonetheless, such findings match our expectations that adding 
palbociclib to letrozole would increase the suppression of cell proliferation. 
In conclusion, the PALLET trial demonstrated that adding palbociclib to letrozole 
markedly enhanced suppression of malignant cell proliferation as measured by Ki67 
expression, yet without an increase in tumor shrinkage as determined by clinical 
ultrasound. Correlating biomarkers of anti-proliferative response in the context of a 
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randomized neo-adjuvant study will be important in determining which patients may 
derive most benefit from CDK4/6 inhibitors in the ongoing adjuvant studies in early 
BC.  
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Figure 1: CONSORT flow diagram  
Randomized (n=307) 
3:2:2:2 
Group B: Letrozole to week 2 
followed by palbociclib plus letrozole 
to week 14 
 Allocated (n=68) 
 Received treatment (n=66) 
 Ineligible but evaluable per ITT 
(n=3) 
 Withdrew consent to collect 
further data (n=1) 
 Unwilling to continue with trial 
related follow-up visits (n=1) 
Group A: Letrozole alone 
 
 
 Allocated (n=103) 
 Received treatment (n=100) 
 Ineligible but evaluable per ITT 
(n=4) 
 Withdrew consent to collect 
further data (n=2) 
 Unwilling to continue with trial 
related follow-up visits (n=1) 
Group C: Palbociclib to week 2 
followed by palbociclib plus letrozole 
to week 14 
 Allocated (n=69) 
 Received treatment (n=69) 
 Ineligible but evaluable per ITT 
(n=0) 
 Withdrew consent to collect 
further data (n=0) 
 Unwilling to continue with trial 
related follow-up visits (n=2) 
Group D: Palbociclib plus letrozole to 
week 14 
 
 Allocated (n=67) 
 Received treatment (n=66) 
 Ineligible but evaluable per ITT 
(n=0) 
 Withdrew consent to collect 
further data (n=0) 
 Unwilling to continue with trial 
related follow up visits (n=1) 
 Evaluable clinical response 
(n=63) 
 Ultrasound measurement not 
evaluable (n=0) 
 Ultrasound not conducted (n=5) 
 Evaluable clinical response (n=93) 
 Ultrasound measurement not 
evaluable (n=0) 
 Ultrasound not conducted (n=10) 
 Evaluable clinical response 
(n=61) 
 Ultrasound measurement not 
evaluable (n=1) 
 Ultrasound not conducted (n=7) 
 Evaluable clinical response 
(n=62) 
 Ultrasound measurement not 
evaluable (n=0) 
 Ultrasound not conducted (n=5) 
 Evaluable Ki67 response (n=40) 
 Baseline not available (n=3) 
 Week 14 not available (n=20) 
 Baseline and week 14 not 
available (n=5) 
 Evaluable Ki67 response (n=65) 
 Baseline not available (n=3) 
 Week 14 not available (n=29) 
 Baseline and week 14 not 
available (n=6) 
 Evaluable Ki67 response (n=47) 
 Baseline not available (n=2) 
 Week 14 not available (n=17) 
 Baseline and week 14 not 
available (n=3) 
 Evaluable Ki67 response (n=38) 
 Baseline not available (n=4) 
 Week 14 not available (n=20) 
 Baseline and week 14 not 
available (n=5) 
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Figure 2: (A) Waterfall plot of log-fold change and percentage change in Ki67 between 
baseline and the end of treatment1 and (B) spaghetti plots of individual trajectories of 
Ki67 by randomized treatment group 
(Attached as PDF) 
  
                                            
1
 Five patients had a percentage increase greater than 125% 
 PALLET manuscript v3.0   24 
 
Figure 3: (A) Waterfall plot of log-fold change and percentage change in c-PARP 
between baseline and the end of treatment2 (B) spaghetti plots of individual 
trajectories of c-PARP by randomized treatment group 
(Attached as PDF) 
                                            
2
 Five patients had a percentage increase greater than 125% 
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Table 1: Baseline demographic and clinical characteristics by randomized treatment group3 
  
Letrozole alone 
 
Letrozole+Palbociclib 
from week 2 
Palbociclib+Letrozole 
from week 2 
Palbociclib+Letrozole 
 
Palbociclib+letrozole 
regimen 
Group A Group B Group C Group D Groups B, C and D 
(N=103) (N=68) (N=69) (N=67) (N=204) 
Median IQR Median IQR Median IQR Median IQR Median IQR 
Age (years) 
65.8 
59.4-
72.0 
66.3 
60.4-
72.5 
63.5 59.3-70.5 63.8 58.5-69.1 64.4 59.5-71.1 
 n % n % n % n % n % 
Recruitment region           
   UK 56 42.4 37 54.4 37 53.6 36 53.7 110 53.9 
   North America 47 45.6 31 45.6 32 46.4 31 46.3 94 46.1 
Tumor grade                     
   Low 13 12.6 6 8.8 4 5.8 9 13.4 19 9.3 
   Intermediate 70 68.0 54 79.4 52 75.4 51 76.1 157 77.0 
   High 19 18.5 7 10.3 13 18.8 7 10.5 27 13.2 
   Not known 1 1.0 1 1.5 0 0.0 0 0.0 1 0.5 
Histological type           
   Ductal 74 71.8 49 72.1 46 66.7 45 67.2 140 68.7 
   Lobular 24 23.3 14 20.6 19 27.5 18 26.9 51 25.0 
   Mixed ductal and lobular 4 3.9 1 1.5 4 5.8 2 3.0 7 3.4 
   Mucinous 1 1.0 4 5.9 0 0.0 2 3.0 6 2.9 
ER status           
   Positive 103 100.0 68 100.0 69 100.0 67 100.0 204 100.0 
PgR status           
   Positive 74 71.8 47 69.1 41 59.4 53 79.1 141 69.1 
   Negative 15 14.6 10 14.7 15 21.7 7 10.5 32 15.7 
   Not determined 14 13.7 11 16.2 13 18.8 7 10.5 31 15.2 
Surgical intent at baseline           
   Partial mastectomy/lumpectomy 61 59.2 45 66.2 40 58.0 39 58.2 124 60.8 
                                            
3
 See supplementary materials (results section) for information on the associations between baseline characteristics and availability of Ki67 results. 
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   Total or modified radical mastectomy 39 37.9 20 29.4 25 36.2 24 35.8 69 33.8 
   Missing 3 2.9 3 4.4 4 5.8 4 6.0 11 5.4 
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Table 2: Endpoint by randomized treatment group 
 
Letrozole alone 
 
Letrozole+Palbociclib 
from week 2 
Palbociclib+Letrozole 
from week 2 
Palbociclib+Letrozole 
 
Palbociclib+Letrozole 
regimens 
Group A  
(N=93) 
Group B  
(N=63) 
Group C  
(N=61) 
Group D  
(N=62) 
Groups B, C 
and D (N=186) 
N % N % N % N % N % 
Clinical response           
Complete response 2 2.2 1 1.6 2 3.3 1 1.6 4 2.2 
Partial response 44 47.3 30 47.6 33 54.1 34 54.8 97 52.2 
Stable disease 42 45.2 30 47.6 25 41.0 24 38.7 79 42.5 
Progressive disease 5 5.4 2 3.2 1 1.6 3 4.8 6 3.2 
Pathological complete response 
Group A  
(N=87) 
Group B  
(N=60) 
Group C  
(N=60) 
Group D  
(N=60) 
Groups B, C 
and D (N=180) 
pCR breast (any nodal status) 1 1.1 1 1.7 3 5.0 2 3.3 6 3.3 
pCR breast & nodes 0 0.0 1 1.7 1 1.7 0 0.0 2 1.1 
Log-fold change in Ki67 
Group A Group B Group C Group D Groups B, C and D 
N Med IQR N Med IQR N Med IQR N Med IQR N Med IQR 
From baseline to week 14 65 -2.2 -3.4 – -1.0 40 -4.1 -5.1 – -2.7 47 -4.0 -5.1 – -3.0 38 -3.9 -5.0 – -2.9 125 -4.1 -5.0 – -2.8 
From baseline to week 2 61 -1.3 -2.8 – -0.6 39 -1.3 -2.5 – -0.8 44 -3.1 -4.1 – -1.5 32 -3.9 -4.7 – -2.7 115 -2.8 -4.1 – -1.2 
From week 2 to week 14 61 -0.1 -1.1 – 0.4 39 -2.1 -3.5 – -1.3 44 -0.4 -2.1 – 0.0 32 0.0 -0.1 – 0.9 115 -1.0 -2.2 – 0.0 
Log-fold change in c-PARP N Med IQR N Med IQR N Med IQR N Med IQR N Med IQR 
From baseline to week 14 47 -0.4 -1.0 – 0.2 34 -0.9 -1.4 – -0.5 37 -0.8 -1.4 – -0.2 28 -0.6 -1.3 – -0.2 99 -0.8 -1.4 – -0.3 
From baseline to week 2 42 -0.1 -0.5 – -0.3 31 -0.3 -0.7 – -0.1 36 -0.3 -0.8 – -0.2 23 -0.5 -0.7 – 0.0 90 -0.4 -0.7 – -0.1 
From week 2 to week 14 42 -0.3 -0.8 – 0.0 31 -0.6 -1.2 – -0.3 36 -0.3 -0.8 – 0.1 23 -0.3 -0.7 – 0.1 90 -0.4 -0.9 – 0.0 
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Table 3: Most frequently occurring Adverse Events  
The table contains the number of patients experiencing any grade or grade ≥3 as per 
MedDRA preferred term AEs. Sorted by most frequent AE of any grade occurring overall. 
Only AEs occurring in more than 10% of patients in Group A or in the palbociclib+letrozole 
groups are reported. Percentages within group based on the as-treated populations. 
 
Letrozole alone 
Group A (N=100) 
Palbociclib+letrozole regimen 
Groups B+C+D (N=201) 
MedDRA coded AE preferred term 
Any grade 
n (%) 
Grade ≥3 
n (%) 
Any grade  
n (%) 
Grade ≥3 
n (%) 
Fatigue 41 (41.0) 0 (0.0) 117 (58.2) 4 (2.0) 
Neutrophil count decreased 2 (2.0) 0 (0.0) 110 (54.7) 82 (40.8) 
Hot flush 40 (40.0) 0 (0.0) 54 (26.9) 0 (0.0) 
Nausea 18 (18.0) 0 (0.0) 50 (24.9) 0 (0.0) 
Arthralgia 26 (26.0) 0 (0.0) 37 (18.4) 1 (0.5) 
Headache 21 (21.0) 0 (0.0) 37 (18.4) 0 (0.0) 
White blood cell count decreased 1 (1.0) 0 (0.0) 49 (24.4) 12 (6.0) 
Diarrhea 14 (14.0) 1 (1.0) 33 (16.4) 2 (1.0) 
Constipation 10 (10.0) 0 (0.0) 26 (12.9) 0 (0.0) 
Breast pain 12 (12.0) 0 (0.0) 20 (10.0) 1 (0.5) 
Platelet count decreased 0 (0.0) 0 (0.0) 31 (15.4) 0 (0.0) 
Dizziness 7 (7.0) 0 (0.0) 24 (11.9) 0 (0.0) 
Alanine aminotransferase increased 7 (7.0) 0 (0.0) 23 (11.4) 8 (4.0) 
Alopecia 3 (3.0) 0 (0.0) 26 (12.9) 0 (0.0) 
Hypertension 11 (11.0) 8 (8.0) 15 (7.5) 9 (4.5) 
Cough 3 (3.0) 0 (0.0) 21 (10.4) 0 (0.0) 
Anemia 3 (3.0) 0 (0.0) 20 (10.0) 0 (0.0) 
Epistaxis 2 (2.0) 0 (0.0) 20 (10.0) 0 (0.0) 
Stomatitis 0 (0.0) 0 (0.0) 20 (10.0) 2 (1.0) 
Depression 10 (10.0) 0 (0.0) 9 (4.5) 0 (0.0) 
Pain in extremity 10 (10.0) 1 (1.0) 9 (4.5) 0 (0.0) 
Myalgia 11 (11.0) 0 (0.0) 8 (4.0) 0 (0.0) 
 
 
